Bilal Wazir Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bilal Wazir Khan has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Huzaifa Khattak
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
8 shared publications Tayyaba Ikram Qazi
8 shared publicationsMuhammad Huzaifa Khattak
7 shared publicationsHaris Wazir Khan
Department of Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan
6 shared publicationsMuhammad Faaz Khan
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
6 shared publications- Tayyaba Ikram Qazi
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
5 shared publications
Latest Publications
- 24 September 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-18
Efficacy and safety of edaravone dexborneol in acute ischemic stroke patients undergoing endovascular thrombectomy: a systematic review and meta-analysis
Acute ischemic stroke (AIS) causes disability. Edaravone–dexborneol (ED) acts through antioxidant and anti-inflammatory mechanisms. This meta-analysis evaluated ED as an adjunct to endovascular thrombectomy (EVT). Databases were searched through July 2026 for studies comparing ED with control in AIS patients undergoing EVT. The primary outcome was 90-day functional independence (mRS 0–2). Hartung-Knapp random-effects models, RoB 2, ROBINS-I, and GRADE were used. Eight studies (4 RCTs and 4 observational studies; n = 5101) were included. However, the number of participants contributing to each pooled analysis varied according to outcome availability. Notably, all eight included studies were conducted exclusively in China. Five studies involving 2057 patients contributed to the primary outcome analysis. The overall pooled analysis failed to show a statistically significant improvement in functional independence (RR 1.26; 95% CI 0.90–1.77), indicating substantial uncertainty in the combined evidence. RCTs showed improved functional independence (RR 1.11; 95% CI 1.04–1.19) and reduced hemorrhagic transformation (RR 0.55; 95% CI 0.46–0.66). Other outcomes showed no significant differences. Current evidence does not demonstrate a statistically significant overall benefit of ED on functional independence, though a modest improvement was observed in randomized trials alone. While ED was associated with reduced hemorrhagic transformation without an increase in major safety events, these results are derived exclusively from Chinese cohorts and are limited by unadjusted observational data. These findings must be interpreted with caution, and larger, multi-national randomized trials are required to determine true efficacy and global applicability.
- 24 September 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-18
Efficacy and safety of edaravone dexborneol in acute ischemic stroke patients undergoing endovascular thrombectomy: a systematic review and meta-analysis
Acute ischemic stroke (AIS) causes disability. Edaravone–dexborneol (ED) acts through antioxidant and anti-inflammatory mechanisms. This meta-analysis evaluated ED as an adjunct to endovascular thrombectomy (EVT). Databases were searched through July 2026 for studies comparing ED with control in AIS patients undergoing EVT. The primary outcome was 90-day functional independence (mRS 0–2). Hartung-Knapp random-effects models, RoB 2, ROBINS-I, and GRADE were used. Eight studies (4 RCTs and 4 observational studies; n = 5101) were included. However, the number of participants contributing to each pooled analysis varied according to outcome availability. Notably, all eight included studies were conducted exclusively in China. Five studies involving 2057 patients contributed to the primary outcome analysis. The overall pooled analysis failed to show a statistically significant improvement in functional independence (RR 1.26; 95% CI 0.90–1.77), indicating substantial uncertainty in the combined evidence. RCTs showed improved functional independence (RR 1.11; 95% CI 1.04–1.19) and reduced hemorrhagic transformation (RR 0.55; 95% CI 0.46–0.66). Other outcomes showed no significant differences. Current evidence does not demonstrate a statistically significant overall benefit of ED on functional independence, though a modest improvement was observed in randomized trials alone. While ED was associated with reduced hemorrhagic transformation without an increase in major safety events, these results are derived exclusively from Chinese cohorts and are limited by unadjusted observational data. These findings must be interpreted with caution, and larger, multi-national randomized trials are required to determine true efficacy and global applicability.
- 19 September 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-27
Transradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of 32 studies
1. Diagnostic cerebral angiography is the gold standard for evaluating cerebrovascular pathologies, including intracranial aneurysms, arteriovenous malformations, carotid artery stenosis, and vascu...
- 19 September 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-27
Transradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of 32 studies
1. Diagnostic cerebral angiography is the gold standard for evaluating cerebrovascular pathologies, including intracranial aneurysms, arteriovenous malformations, carotid artery stenosis, and vascu...
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer
Objectives: Sacituzumab govitecan (SG), a Trop-2–directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to evaluate the effectiveness and safety of SG using only randomized controlled trials (RCTs). Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed/MEDLINE, Embase, Scopus, and Cochrane Library were searched from June 2025 to April 2026. RCTs comparing SG with standard therapies in breast cancer patients were included. Outcomes included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and grade ≥3 adverse events. Random-effects models were used to calculate pooled risk ratios (RR) and hazard ratios (HR) with 95% CIs. Risk of bias (RoB 2) and GRADE approaches were applied. Results: Six RCTs (n=2508) were included. SG significantly improved ORR (RR=1.62; 95% CI: 1.11-2.37), OS (HR=0.68; 95% CI: 0.54-0.86), and PFS (HR=0.60; 95% CI: 0.51-0.72), although heterogeneity was moderate to high in some analyses. SG was associated with a higher risk of grade ≥3 adverse events (RR=1.12; 95% CI: 1.05-1.20), particularly diarrhea and neutropenia. Subgroup and sensitivity analyses confirmed the robustness of efficacy outcomes. Conclusions: SG provides significant improvements in survival and response outcomes in advanced breast cancer, with a manageable toxicity profile. These findings support its role as an effective treatment option, particularly in pretreated patients, while highlighting the need for further research to optimize its clinical use.
- Open Access
- 11 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9)
Culture‐Negative Septic Pulmonary Embolism Secondary to Lower‐Limb Cellulitis Following Recent Dengue Fever Complicated by Hydropneumothorax: A Case Report
Secondary bacterial infection and septic pulmonary embolism should be considered in patients recovering from dengue fever who develop focal soft‐tissue infection, respiratory symptoms, or markedly elevated inflammatory markers. Characteristic radiological findings may establish the diagnosis even when blood cultures are negative and infective endocarditis is absent.
- 11 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9)
Open AccessCulture‐Negative Septic Pulmonary Embolism Secondary to Lower‐Limb Cellulitis Following Recent Dengue Fever Complicated by Hydropneumothorax: A Case Report
Secondary bacterial infection and septic pulmonary embolism should be considered in patients recovering from dengue fever who develop focal soft‐tissue infection, respiratory symptoms, or markedly elevated inflammatory markers. Characteristic radiological findings may establish the diagnosis even when blood cultures are negative and infective endocarditis is absent.
- 17 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.
- 17 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain. Methods: PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to February 2026. Phase II/III RCTs comparing carboplatin plus standard chemotherapy with standard therapy alone in TNBC were included. Primary outcomes were disease-free survival (DFS), overall survival (OS), and pathological complete response (pCR). Pooled hazard ratios (HRs) and risk ratios (RRs) were calculated using random-effects models. Results: Twenty-three trials (n = 8797) were included. Carboplatin significantly improved DFS (HR 0.68, 95% CI 0.60–0.76), OS (HR 0.65, 95% CI 0.53–0.80), and pCR (RR 1.46, 95% CI 1.30–1.64). Improvements were also observed in distant disease-free survival and recurrence-free survival. However, carboplatin was associated with increased hematological toxicities, including anemia, neutropenia, and thrombocytopenia, and higher rates of dose reduction and treatment discontinuation, though treatment-related mortality was not significant. Conclusion: Carboplatin-containing chemotherapy improves survival outcomes and pCR in TNBC. Despite increased toxicity, adverse effects are generally manageable. These findings support the incorporation of carboplatin into TNBC treatment, with careful patient selection to balance efficacy and safety.
- 10 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10001-10017
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Purpose: To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials. Methods: This systematic review and meta‐analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420261303350). PubMed, Embase and Scopus were searched from inception to March 2026 for randomised controlled trials comparing oral PCSK9 inhibitors with placebo in adults with hypercholesterolemia. Primary outcomes were changes in low‐density lipoprotein cholesterol (LDL‐C) and triglycerides. Secondary outcomes included other lipid parameters, adverse events and mortality. Random‐effects models were used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Quality of the included studies was assessed using the RoB2 tool and certainty of evidence was assessed using the GRADE approach. Results: Five randomised controlled trials ( n = 4268) were included. Oral PCSK9 inhibitors significantly reduced LDL‐C (MD −49.49 mg/dL; 95% CI −54.81 to −44.18; p < 0.00001) and triglycerides (MD −11.65 mg/dL; 95% CI −15.53 to −7.78; p < 0.00001). Significant reductions were also observed in non‐HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol. Dose‐dependent effects were noted, with greater reductions at higher doses. No significant differences were observed in mortality or overall adverse events. Treatment discontinuation due to adverse events was lower with intervention. Conclusions: Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short‐term safety profile. However, the available evidence is derived primarily from short‐term randomised trials evaluating surrogate lipid outcomes. Larger randomised trials with longer follow‐up and cardiovascular outcome data are needed to better define the long‐term clinical role of oral PCSK9 inhibitors.
- 10 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10001-10017
Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated and GRADE Assessed Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Purpose: To evaluate the efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia by synthesizing evidence from randomised controlled trials. Methods: This systematic review and meta‐analysis followed PRISMA guidelines and was registered on PROSPERO (CRD420261303350). PubMed, Embase and Scopus were searched from inception to March 2026 for randomised controlled trials comparing oral PCSK9 inhibitors with placebo in adults with hypercholesterolemia. Primary outcomes were changes in low‐density lipoprotein cholesterol (LDL‐C) and triglycerides. Secondary outcomes included other lipid parameters, adverse events and mortality. Random‐effects models were used to calculate mean differences (MD) and risk ratios (RR) with 95% confidence intervals (CI). Quality of the included studies was assessed using the RoB2 tool and certainty of evidence was assessed using the GRADE approach. Results: Five randomised controlled trials ( n = 4268) were included. Oral PCSK9 inhibitors significantly reduced LDL‐C (MD −49.49 mg/dL; 95% CI −54.81 to −44.18; p < 0.00001) and triglycerides (MD −11.65 mg/dL; 95% CI −15.53 to −7.78; p < 0.00001). Significant reductions were also observed in non‐HDL cholesterol, apolipoprotein B, lipoprotein(a) and total cholesterol. Dose‐dependent effects were noted, with greater reductions at higher doses. No significant differences were observed in mortality or overall adverse events. Treatment discontinuation due to adverse events was lower with intervention. Conclusions: Oral PCSK9 inhibitors were associated with clinically meaningful improvements in multiple lipid parameters while maintaining a favourable short‐term safety profile. However, the available evidence is derived primarily from short‐term randomised trials evaluating surrogate lipid outcomes. Larger randomised trials with longer follow‐up and cardiovascular outcome data are needed to better define the long‐term clinical role of oral PCSK9 inhibitors.